BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 20424152)

  • 1. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.
    Ho E; Brown A; Barrett P; Morgan RB; King G; Kennedy MJ; Murphy RT
    Heart; 2010 May; 96(9):701-7. PubMed ID: 20424152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
    Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
    Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
    BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.
    Negishi K; Negishi T; Haluska BA; Hare JL; Plana JC; Marwick TH
    Eur Heart J Cardiovasc Imaging; 2014 Mar; 15(3):324-31. PubMed ID: 24057661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclinical Anthracycline-Induced Cardiotoxicity in the Long - Term Follow-Up of Lymphoma Survivors: A Multi-Layer Speckle Tracking Analysis.
    Kang Y; Xiao F; Chen H; Wang W; Shen L; Zhao H; Shen X; Chen F; He B
    Arq Bras Cardiol; 2018 Mar; 110(3):219-228. PubMed ID: 29694546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.
    Hare JL; Brown JK; Leano R; Jenkins C; Woodward N; Marwick TH
    Am Heart J; 2009 Aug; 158(2):294-301. PubMed ID: 19619708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity.
    Negishi K; Negishi T; Hare JL; Haluska BA; Plana JC; Marwick TH
    J Am Soc Echocardiogr; 2013 May; 26(5):493-8. PubMed ID: 23562088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
    Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
    Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
    Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients.
    Mele D; Malagutti P; Indelli M; Ferrari L; Casadei F; Da Ros L; Pollina A; Fiorencis A; Frassoldati A; Ferrari R
    Ultrasound Med Biol; 2016 Jan; 42(1):125-32. PubMed ID: 26603736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of Echocardiographic Techniques to Detect Subclinical Cancer Therapeutics-Related Cardiac Dysfunction among High-Dose Patients When Compared with Cardiac Magnetic Resonance Imaging.
    Toro-Salazar OH; Ferranti J; Lorenzoni R; Walling S; Mazur W; Raman SV; Davey BT; Gillan E; O'Loughlin M; Klas B; Hor KN
    J Am Soc Echocardiogr; 2016 Feb; 29(2):119-31. PubMed ID: 26678319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
    Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
    Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial.
    Nabati M; Janbabai G; Esmailian J; Yazdani J
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):233-241. PubMed ID: 30599756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline-Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients.
    Lange SA; Jung J; Jaeck A; Hitschold T; Ebner B
    Cardiovasc Toxicol; 2016 Apr; 16(2):193-206. PubMed ID: 26022230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy.
    Jassal DS; Han SY; Hans C; Sharma A; Fang T; Ahmadie R; Lytwyn M; Walker JR; Bhalla RS; Czarnecki A; Moussa T; Singal PK
    J Am Soc Echocardiogr; 2009 Apr; 22(4):418-24. PubMed ID: 19269133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility.
    Santoro C; Arpino G; Esposito R; Lembo M; Paciolla I; Cardalesi C; de Simone G; Trimarco B; De Placido S; Galderisi M
    Eur Heart J Cardiovasc Imaging; 2017 May; 18(8):930-936. PubMed ID: 28379383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
    Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
    BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.